Novartis Pharmaceuticals UK Limited Sustainability Profile
Novartis Pharmaceuticals UK Limited, a prominent player in the global healthcare landscape, is headquartered in Great Britain. Established in 1996, the company has made significant strides in the pharmaceutical industry, focusing on innovative medicines and advanced therapies across various therapeutic areas, including oncology, cardiology, and immunology. With a commitment to research and development, Novartis is renowned for its unique portfolio of prescription medications and cutting-edge treatments that address unmet medical needs. The company has achieved notable milestones, including the launch of groundbreaking therapies that have transformed patient care. As a leader in the pharmaceutical sector, Novartis Pharmaceuticals UK Limited continues to enhance its market position through strategic partnerships and a robust pipeline of products, solidifying its reputation for excellence in healthcare innovation.
DitchCarbon Score
How does Novartis Pharmaceuticals UK Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis Pharmaceuticals UK Limited's score of 75 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis Pharmaceuticals UK Limited's reported carbon emissions
In 2023, Novartis Pharmaceuticals UK Limited reported total carbon emissions of approximately 4,710,409,000 kg CO2e. This figure includes 245,725,000 kg CO2e from Scope 1 emissions, 44,102,000 kg CO2e from Scope 2 emissions, and a significant 4,420,582,000 kg CO2e from Scope 3 emissions. This represents a decrease from 2022, when total emissions were about 5,237,736,000 kg CO2e, with Scope 1 at 258,757,000 kg CO2e, Scope 2 at 106,579,000 kg CO2e, and Scope 3 at 4,829,157,000 kg CO2e. Novartis has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 73% by 2030, using 2019 as the baseline year. Additionally, the company has a long-term goal of achieving net-zero emissions across all scopes by 2045, targeting a 90% reduction in absolute emissions compared to the 2019 baseline. These targets are part of a broader commitment to sustainability, with data cascaded from its parent company, Novartis AG, which oversees various climate initiatives including SBTi, CDP, and RE100. The emissions data and reduction targets reflect Novartis Pharmaceuticals UK Limited's ongoing efforts to address climate change and enhance environmental responsibility within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 343,149,000 |
| Scope 2 | 147,501,000 |
| Scope 3 | 7,663,118,000 |
How Carbon Intensive is Novartis Pharmaceuticals UK Limited's Industry?
How Carbon Intensive is Novartis Pharmaceuticals UK Limited's Location?
Novartis Pharmaceuticals UK Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novartis Pharmaceuticals UK Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
